LAUSR

Background.  Myeloproliferative neoplasms (MPN) are disorders characterized by an alteration at the hematopoietic stem cell (HSC) level, where the JAK2 mutation is the most common genetic alteration found in classic MPN (polycythemia vera, essential thrombocythemia, and primary myelofibrosis). We and others previously demonstrated that metformin reduced splenomegaly and platelets counts in peripheral blood in JAK2 V617F pre-clinical MPN models, which highlighted the antineoplastic potential of biguanides for MPN treatment. Phenformin is a biguanide that has been used to treat diabetes, but was withdrawn due to its potential to cause lactic acidosis in patients. Aims . We herein aimed to investigate the effects of phenformin in MPN disease burden and stem cell function in Jak2 V617F -knockin MPN mice. Results . In vitro phenformin treatment reduced cell viability and increased apoptosis in SET2 JAK2 V67F cells. Long-term treatment with 40 mg/kg phenformin in Jak2 V617F knockin mice increased the frequency of LSK, myeloid progenitors (MP), and multipotent progenitors (MPP) in the bone marrow. Phenformin treatment did not affect peripheral blood counts, spleen weight, megakaryocyte count, erythroid precursors frequency, or ex vivo clonogenic capacity. Ex vivo treatment of bone marrow cells from Jak2 V617F knockin mice with phenformin did not affect hematologic parameters or engraftment in recipient mice. Conclusions . Phenformin increased the percentages of LSK, MP, and MPP populations, but did not reduce disease burden in Jak2 V617F -knockin mice. Additional studies are necessary to further understand the effects of phenformin on early hematopoietic progenitors.